Megan M. Tu

1.2k total citations
21 papers, 757 citations indexed

About

Megan M. Tu is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Megan M. Tu has authored 21 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 11 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Megan M. Tu's work include Immune Cell Function and Interaction (12 papers), T-cell and B-cell Immunology (8 papers) and Immunotherapy and Immune Responses (5 papers). Megan M. Tu is often cited by papers focused on Immune Cell Function and Interaction (12 papers), T-cell and B-cell Immunology (8 papers) and Immunotherapy and Immune Responses (5 papers). Megan M. Tu collaborates with scholars based in Canada, Saudi Arabia and United States. Megan M. Tu's co-authors include Andrew P. Makrigiannis, Ahmad Bakur Mahmoud, Mir Munir A. Rahim, Andrew Wight, Elias Abou-Samra, Patricia D.A. Lima, Dan Theodorescu, Christopher J. Rivard, James C. Costello and Jason E. Duex and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Megan M. Tu

20 papers receiving 746 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Megan M. Tu Canada	14	467	355	156	100	61	21	757
Myriam Lawand France	10	509 1.1×	372 1.0×	72 0.5×	122 1.2×	49 0.8×	14	727
Joy Hsu United States	8	731 1.6×	581 1.6×	100 0.6×	214 2.1×	41 0.7×	16	1.0k
Jochen T. Schaefer United States	11	430 0.9×	480 1.4×	81 0.5×	151 1.5×	64 1.0×	17	802
Robert Sanchez Rodriguez United States	6	379 0.8×	416 1.2×	58 0.4×	104 1.0×	27 0.4×	10	607
Hyungjun Jeon United States	10	427 0.9×	440 1.2×	90 0.6×	81 0.8×	35 0.6×	11	658
Benjamin Cottam United States	11	628 1.3×	672 1.9×	124 0.8×	153 1.5×	33 0.5×	14	949
Myrna Rauckhorst United States	12	550 1.2×	707 2.0×	270 1.7×	186 1.9×	48 0.8×	25	971
Verena Voelter Switzerland	16	568 1.2×	452 1.3×	56 0.4×	219 2.2×	75 1.2×	27	856
Koen A. Marijt Netherlands	10	480 1.0×	408 1.1×	74 0.5×	151 1.5×	29 0.5×	13	672
Michio Naoe Japan	11	387 0.8×	308 0.9×	108 0.7×	265 2.6×	37 0.6×	29	762

Countries citing papers authored by Megan M. Tu

Since Specialization

Citations

This map shows the geographic impact of Megan M. Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan M. Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan M. Tu more than expected).

Fields of papers citing papers by Megan M. Tu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan M. Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan M. Tu. The network helps show where Megan M. Tu may publish in the future.

Co-authorship network of co-authors of Megan M. Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Megan M. Tu. A scholar is included among the top collaborators of Megan M. Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan M. Tu. Megan M. Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guay, Evelyne, Mohammed Ibrahim, Megan M. Tu, et al.. (2021). The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. Critical Reviews in Oncology/Hematology. 169. 103540–103540. 14 indexed citations

Clemons, Mark, Carol Stober, Gregory R. Pond, et al.. (2021). Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. Journal of bone oncology. 30. 100388–100388. 12 indexed citations

Tu, Megan M., Mark Clemons, Carol Stober, et al.. (2021). Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. Current Oncology. 28(3). 1847–1856. 4 indexed citations

Tu, Megan M., Hany Abdel-Hafiz, Robert T. Jones, et al.. (2020). Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Communications Biology. 3(1). 720–720. 125 indexed citations

Ng, Terry L., Megan M. Tu, Mohammed Ibrahim, et al.. (2020). Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Supportive Care in Cancer. 29(2). 925–943. 31 indexed citations

Ng, Terry L., Megan M. Tu, Mohammed Ibrahim, et al.. (2020). Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.. Journal of Clinical Oncology. 38(15_suppl). e24083–e24083.

Tu, Megan M., et al.. (2019). Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. Bladder Cancer. 5(2). 131–145. 12 indexed citations

Jiang, Tao, Zhen Qin, Seung Hee Yang, et al.. (2018). HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Annals of Oncology. 30(3). 447–455. 143 indexed citations

Ren, Shengxiang, Hui Yu, Christopher J. Rivard, et al.. (2018). The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. Lung Cancer. 125. 115–120. 38 indexed citations

10.

Abou-Samra, Elias, Oscar A. Aguilar, Ahmad Bakur Mahmoud, et al.. (2018). NKR-P1B expression in gut-associated innate lymphoid cells is required for the control of gastrointestinal tract infections. Cellular and Molecular Immunology. 16(11). 868–877. 13 indexed citations

11.

Wight, Andrew, Ahmad Bakur Mahmoud, Megan M. Tu, et al.. (2018). Critical role for the Ly49 family of class I MHC receptors in adaptive natural killer cell responses. Proceedings of the National Academy of Sciences. 115(45). 11579–11584. 23 indexed citations

12.

Tu, Megan M., et al.. (2017). Immunosurveillance and Immunoediting of Breast Cancer via Class I MHC Receptors. Cancer Immunology Research. 5(11). 1016–1028. 18 indexed citations

13.

Aguilar, Oscar A., Richard Berry, Mir Munir A. Rahim, et al.. (2017). A Viral Immunoevasin Controls Innate Immunity by Targeting the Prototypical Natural Killer Cell Receptor Family. Cell. 169(1). 58–71.e14. 65 indexed citations

14.

Tu, Megan M., Ahmad Bakur Mahmoud, & Andrew P. Makrigiannis. (2016). Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control. Frontiers in Immunology. 7. 166–166. 48 indexed citations

15.

Felker, Allison M., et al.. (2016). Ly49 knockdown in mice results in aberrant uterine crypt formation and impaired blastocyst implantation. Placenta. 39. 147–150. 5 indexed citations

16.

Chen, Peter, Oscar A. Aguilar, Mir Munir A. Rahim, et al.. (2015). Genetic Investigation of MHC-Independent Missing-Self Recognition by Mouse NK Cells Using an In Vivo Bone Marrow Transplantation Model. The Journal of Immunology. 194(6). 2909–2918. 20 indexed citations

17.

Tu, Megan M., Ahmad Bakur Mahmoud, Andrew Wight, et al.. (2014). Ly49 Family Receptors Are Required for Cancer Immunosurveillance Mediated by Natural Killer Cells. Cancer Research. 74(14). 3684–3694. 28 indexed citations

18.

Rahim, Mir Munir A., Megan M. Tu, Ahmad Bakur Mahmoud, et al.. (2014). Ly49 Receptors: Innate and Adaptive Immune Paradigms. Frontiers in Immunology. 5. 145–145. 71 indexed citations

19.

Tu, Megan M., Lee‐Hwa Tai, Clayton W. Hall, et al.. (2013). Optimized Tetramer Analysis Reveals Ly49 Promiscuity for MHC Ligands. The Journal of Immunology. 191(11). 5722–5729. 7 indexed citations

20.

Bélanger, Simon, Megan M. Tu, Mir Munir A. Rahim, et al.. (2012). Impaired natural killer cell self-education and “missing-self” responses in Ly49-deficient mice. Blood. 120(3). 592–602. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact